Xiaoli Zhu1,2, Qianming Bai1,2, Yongming Lu1,2, Peng Qi1,2, Jianhui Ding2,3, Jialei Wang2,4, Xiaoyan Zhou5,6. 1. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 3. Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 4. Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 5. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. xyzhou100@163.com. 6. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. xyzhou100@163.com.
Abstract
BACKGROUND: The rare epidermal growth factor receptor (EGFR) mutation S768I has only been reported sporadically in patients with lung adenocarcinoma (AC). OBJECTIVE: This study aimed to investigate the prevalence of the S768I mutation in Chinese patients with lung AC and to retrospectively analyze the response of S768I mutants to tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: A total of 6698 tissue specimens of lung AC were collected from the Department of Pathology of Shanghai Cancer Center of Fudan University between 2013 and 2015 and screened for EGFR mutations. Previously reported cases were combined with our data to evaluate the response of the S768I mutants to TKIs. RESULTS: Thirty-five patients (0.52 %, 35/6698) harbored the S768I mutation, including 8 (22.9 %) with just the S768I mutation and 27 (77.1 %) with compound mutations of S768I and other EGFR mutations (including G719X and L858R). The median progression-free survival (PFS) of the 8 cases with available PFS data was 5.0 months (95 % confidential interval: 0.4-9.6 months). We combined our cases with the sporadic cases from 14 previous reports (total 49 cases) to assess the response to TKIs and found that the objective response rate was 40.0 %, 74.9 %, and 60.0 % for S768I-only mutants, S768I+G719X mutants, and S768I+L858R mutants, respectively. CONCLUSIONS: S786I mutation is rare in lung AC and is frequently accompanied by G719X, L858R, or other EGFR mutations. Patients harboring only the S768I mutation appear to be more sensitive to TKIs than those with the wild-type EGFR. The S768I mutation may increase the sensitivity of G719X to TKIs but not the sensitivity of L858R to TKIs.
BACKGROUND: The rare epidermal growth factor receptor (EGFR) mutation S768I has only been reported sporadically in patients with lung adenocarcinoma (AC). OBJECTIVE: This study aimed to investigate the prevalence of the S768I mutation in Chinese patients with lung AC and to retrospectively analyze the response of S768I mutants to tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: A total of 6698 tissue specimens of lung AC were collected from the Department of Pathology of Shanghai Cancer Center of Fudan University between 2013 and 2015 and screened for EGFR mutations. Previously reported cases were combined with our data to evaluate the response of the S768I mutants to TKIs. RESULTS: Thirty-five patients (0.52 %, 35/6698) harbored the S768I mutation, including 8 (22.9 %) with just the S768I mutation and 27 (77.1 %) with compound mutations of S768I and other EGFR mutations (including G719X and L858R). The median progression-free survival (PFS) of the 8 cases with available PFS data was 5.0 months (95 % confidential interval: 0.4-9.6 months). We combined our cases with the sporadic cases from 14 previous reports (total 49 cases) to assess the response to TKIs and found that the objective response rate was 40.0 %, 74.9 %, and 60.0 % for S768I-only mutants, S768I+G719X mutants, and S768I+L858R mutants, respectively. CONCLUSIONS:S786I mutation is rare in lung AC and is frequently accompanied by G719X, L858R, or other EGFR mutations. Patients harboring only the S768I mutation appear to be more sensitive to TKIs than those with the wild-type EGFR. The S768I mutation may increase the sensitivity of G719X to TKIs but not the sensitivity of L858R to TKIs.
Authors: Hiroyuki Yasuda; Eunyoung Park; Cai-Hong Yun; Natasha J Sng; Antonio R Lucena-Araujo; Wee-Lee Yeo; Mark S Huberman; David W Cohen; Sohei Nakayama; Kota Ishioka; Norihiro Yamaguchi; Megan Hanna; Geoffrey R Oxnard; Christopher S Lathan; Teresa Moran; Lecia V Sequist; Jamie E Chaft; Gregory J Riely; Maria E Arcila; Ross A Soo; Matthew Meyerson; Michael J Eck; Susumu S Kobayashi; Daniel B Costa Journal: Sci Transl Med Date: 2013-12-18 Impact factor: 17.956
Authors: Matthew D Hellmann; Boris Reva; Helena Yu; Valerie W Rusch; Naiyer A Rizvi; Mark G Kris; Maria E Arcila Journal: J Thorac Oncol Date: 2014-10 Impact factor: 15.609
Authors: Susumu Kobayashi; Hannah M Canepa; Alexandra S Bailey; Sohei Nakayama; Norihiro Yamaguchi; Michael A Goldstein; Mark S Huberman; Daniel B Costa Journal: J Thorac Oncol Date: 2013-01 Impact factor: 15.609
Authors: Jeonghee Cho; Adam J Bass; Michael S Lawrence; Kristian Cibulskis; Ahye Cho; Shi-Nai Lee; Mai Yamauchi; Nikhil Wagle; Panisa Pochanard; Nayoung Kim; Angela Kj Park; Jonghwa Won; Hyung-Suk Hur; Heidi Greulich; Shuji Ogino; Carrie Sougnez; Douglas Voet; Josep Tabernero; Jose Jimenez; Jose Baselga; Stacey B Gabriel; Eric S Lander; Gad Getz; Michael J Eck; Woong-Yang Park; Matthew Meyerson Journal: Mol Cancer Date: 2014-06-04 Impact factor: 27.401
Authors: Xue Yang; Hanxiao Chen; Hong Zhang; Jianchun Duan; Tongtong An; Jun Zhao; Minglei Zhuo; Meina Wu; Jie Wang Journal: Zhongguo Fei Ai Za Zhi Date: 2015-08
Authors: Antonio Passaro; Umberto Malapelle; Marzia Del Re; Ilaria Attili; Alessandro Russo; Elena Guerini-Rocco; Caterina Fumagalli; Pasquale Pisapia; Francesco Pepe; Caterina De Luca; Federico Cucchiara; Giancarlo Troncone; Romano Danesi; Lorenzo Spaggiari; Filippo De Marinis; Christian Rolfo Journal: ESMO Open Date: 2020-10